Nurix Therapeutics Q1 GAAP EPS $(0.76) Beats $(0.80) Estimate, Sales $16.59M Miss $16.64M Estimate
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics (NASDAQ:NRIX) reported Q1 GAAP EPS of $(0.76), surpassing the $(0.80) estimate, but missed sales estimates with $16.59M against the expected $16.64M. This represents a slight decrease in losses per share compared to last year, but a significant increase in sales.
April 10, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Nurix Therapeutics reported a smaller-than-expected quarterly loss and a significant year-over-year increase in sales, though it slightly missed sales estimates.
The mixed results with a beat on EPS but a miss on sales could lead to neutral market reaction. The significant year-over-year sales growth is positive, but the slight miss on sales estimates may temper optimism.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90